Histopathologic abundance of pigmentation correlates with disease‐specific survival in malignant melanoma but is not independent of current AJCC pT stage

Abstract

AbstractThe increasing number of melanoma patients makes it necessary to develop best possible strategies for prognosis assessment in order to recommend appropriate therapy and follow‐up. The prognostic significance of tumor cell pigmentation has not been fully elucidated. Hematoxylin and eosin (H&E)‐stained sections of 775 melanomas diagnosed between 2012 and 2015 were independently assessed for melanin pigment abundance by two investigators, and the impact on melanoma‐specific survival was calculated. Unpigmented melanomas (n = 99) had a melanoma‐specific survival of 67.7%, melanomas with moderate pigmentation (n = 384) had a melanoma‐specific survival of 85.9%, and strongly pigmented melanomas (n = 292) had a melanoma‐specific survival of 91.4% (p < .001). In an analysis of melanoma‐specific survival adjusted for pT stage and pigmentation, we found a nonsignificant impact of pigmentation abundance with a hazard ratio of 1.277 (p = .74). The study presented here provides evidence in a German cohort that patients with pigmented melanomas have a more favorable prognosis than those diagnosed with nonpigmented melanomas. Moreover, the abundance of pigmentation already seems to provide a first prognostic estimate. However, it does not appear to provide significant additional value for prognostic assessment according to the AJCC 2017 pT classification.